
Legend Capital and Zhongjinqichen, a healthcare, technology and consumer-focused private equity fund under China International Capital Co., Ltd have lead a RMB250 million (US$38 million) series B round in Bellen, a Chinese medical contract research organization (CRO).

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!